|Daily Range||$146.16 - $147.50|
|52-Week Range||$124.36 - $150.63|
|Dividend (Yield)||$0.00 (1.4%)|
|Average Daily Volume||64,682|
|Current FY EPS||$7.91|
News & Commentary
Three Motley Fool experts tell readers what upcoming FDA decisions have caught their eye.
Biogen Idec, Regeneron, and Amgen Inc. may be better bets than Gilead Sciences.
Regeneron reported its fourth-quarter and full-year numbers this morning. Here's what investors need to know.
Opthotech Corporation is researching a new therapy for wet-stage age-related macular degeneration that could have blockbuster potential.
It's time for tech investors to acknowledge the potential of sneaky R&D projects in synthetic biology at Autodesk, Intel, and Microsoft.
Ophthotech Corporation, Achillion Pharmaceuticals, and Portola Pharmaceuticals all have catalysts that could lift shares in 2015.
The iShares MSCI EAFE Exchange Traded Fund offers instant international diversification among top companies in top countries for a reasonably low overhead cost.
Three Motley Fool analysts tell investors which biotechnology stocks are on their wish list this month.
Three Motley Fool analysts tell investors which three companies they think would be ripe for an acquisition.
Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.